Targeting mir130b-IL-33-PD-L1 axis effectively inhibits esophageal squamous carcinoma progression Authors: Ying Yue, Wei Xian, Yi Yuan, Xinyue Wang, Peng Wu, Xiaoyu Sha, Xiangyu Yue Published: 2026 ABSTRACT Highlights•A novel miR-130b–RUNX3–IL-33–PD-L1 axis driving ESCC progression is identified.•IL-33 is an independent prognostic marker linked to advanced stage and poor outcome.•PD-L1 blockade reverses IL-33-induced tumor progression, supporting dual-targeted therapy.•miR-130b overexpression suppresses tumor growth in vivo, highlighting therapeutic potential. Introduction Esophageal cancer represents a significant global health burden, ranking as the seventh most prevalent malignancy and the sixth leading cause of cancer-related mortality worldwide [1]. Epidemiological data indicate a marked geographic distribution, with China accounting for approximately 50% of global cases, of which more than half originate from the Henan Province, suggesting potential influence of regional etiological factors [2]. Despite advances in oncology, the therapeutic approach for esophageal cancer remains largely dependent on conventional chemotherapy and radiotherapy [3,4]. The lack of molecularly targeted therapies contributes to persistently poor clinical outcomes, with a 5-year survival rate of just 20% [5]. We conducted a preliminary investigation of the molecular mechanisms underlying esophageal cancer by integrating characteristic cancer-associated genes and bioinformatic analyses of gene functions in cancer tissues [6]. The tumor microenvironment in esophageal cancer exhibits an intricate interplay between immune cells and other stromal cells, where immune cells and their cytokines play critical roles in modulating the anti-tumor immune responses [7]. Dysregulation of these interactions facilitates tumor immune evasion, which is a critical barrier to effective treatment [8]. Additionally, the propensity for early hematogenous and lymphatic dissemination contributes significantly to treatment failure and poor prognosis. Consequently, understanding the molecular mechanisms underlying immune escape in esophageal cancer and identifying novel therapeutic targets remain critical priorities in clinical oncology. Interleukin-33 (IL-33), a multifunctional cytokine belonging to the interleukin-1 (IL-1) family, [9,10] has recently emerged as a critical regulator of tumor immunology [11]. Structurally, IL-33 comprises distinct N-terminal and C-terminal domains, enabling its dual functionality in gene expression regulation and immune response modulation [12]. The biological effects of IL-33 are highly context-dependent and influenced by the surrounding microenvironment. Its activity is tightly regulated through various regulatory mechanisms, including post-transcriptional regulation by microRNAs (miRNAs). miRNAs function as drivers or suppressors of cancer signatures during tumorigenesis and progression, and aberrant microRNA expression promotes or suppresses tumor metastasis by regulating the expression of numerous target genes [13,14]. Notably, miRNA-130b-3p has been implicated in tumor promotion in non-small cell lung cancer, [15] suggesting a potential regulatory network involving IL-33 [16]. Mechanistically, IL-33 exerts its biological functions through direct interaction with the promoter region of IL-33 and the NF-κB subunit p65/RelA, thereby driving transcription activation of these genes. Furthermore, IL-33 functions as a transcriptional cofactor for various transcription factors (e.g., p65, RUNX2, pSTAT3, and FAK) by either inhibiting or enhancing their binding to target sites [17]. The diverse nuclear functions of IL-33 are crucial regulators of cellular processes, such as proliferation, migration, and activation, suggesting its potential involvement in tumorigenesis, [18] metastatic progression, and tumor immune regulation [19]. The RUNX genes play unique roles in development and adult tissue homeostasis. They all act as master regulators, albeit in different tissues, and are implicated in cancer [20]. RUNX3 exerts a crucial role in regulating the biocytological behaviors of ESCC cell migration, invasion, and tumorigenesis [21]. Previously, we detected the expression of programmed death-ligand 1 (PD-L1) and IL-33 mRNA in the tumor tissues of patients with esophageal squamous carcinoma [22,23]. and found a correlation between the two. According to the TCGA database, PD-L1 expression is higher in esophageal cancer tissues than in adjacent normal tissues, and patients with high PD-L1 expression exhibit a poorer prognosis. The regulatory landscape of PD-L1, a critical immune checkpoint molecule, is complicated by miRNA-mediated mechanisms [24]. miRNAs can directly bind to PD-L1 mRNA or indirectly influence its expression by interacting with mRNAs that regulate PD-L1 [25,26]. We propose a novel mechanistic hypothesis, wherein miR-130b modulation influences IL-33 expression through its interaction with RUNX3. Subsequent secretion of IL-33 initiates a signaling cascade via ST2 receptor engagement, leading to mTORC1 pathway activation and consequent PD-L1 upregulation, ultimately driving esophageal squamous carcinoma progression. We aimed to delineate the molecular pathogenesis of ESCC progression and identify novel therapeutic targets, thereby providing innovative perspectives for the development of targeted therapies for esophageal cancer. Materials and methods Collection of tissue specimens Patients aged 40–70 years, diagnosed with esophageal cancer in the oncology department, were selected for the study. Patients with an unclear pathological diagnosis, comorbid immune system disorders, or those who had undergone preoperative antitumor therapy were excluded. For tissue specimen collection, freshly resected tumors and adjacent normal tissues were immediately placed on ice and processed within one hour. Following pathological assessment, data from patients with a confirmed diagnosis of esophageal cancer were included in the statistical analysis. Paraffin-embedded sections were prepared from pathologically confirmed esophageal cancer specimens. Fluorescence quantitative PCR 2 × 10⁵ to 2 × 10⁶ cells were resuspended in 1 mL of TRIzol and mixed thoroughly by pipetting. Total RNA was extracted according to the manufacturer’s instructions. After genomic DNA removal, 1.0 g of total RNA was extracted and reverse-transcribed into cDNA. The cDNA was used as a template, and SYBR®Premix ExTaqTM II was applied for PCR amplification. GAPDH was used as an internal reference to calculated using the 2^−ΔΔCt method using the formula Fold change = 2-ΔΔCt [27]. We then evaluated the mRNA expression levels of IL-33, PD-L1, and miR-130b in tumor tissues, tumor cells, and transfected cells. The experiment was performed with three independent biological replicates, and the mean value was calculated [23]. Cellular immunofluorescence analysis Cells were allowed to adhere to the surface before being subjected to treatments such as drug administration or transfection. Subsequently, the cells were fixed in 4% paraformaldehyde, permeabilized with phosphate-buffered saline (PBS) containing 1% Triton X-100, and blocked with PBS supplemented with 3–5% bovine serum albumin (BSA) or goat serum [28]. Following overnight incubation with the primary antibody, the cells were incubated with the secondary antibody, stained for nuclei, and imaged. Negative and positive controls were established for each staining procedure. MTT experiment The cell viability of each group was assessed to observe the effects of miR-130b and IL-33 downregulation or overexpression on the proliferative ability of tumor cells. Transwell experiments Migration Assay: A total of 500 µL of complete medium was placed into the lower chamber of a 24-well plate. Subsequently, 20,000 cells were resuspended in 200 µL of serum-free RMPI-1640 to form a single-cell suspension, which was then seeded in the upper compartment of the Transwell and incubated for 24 h. Following incubation, the cells were washed three times with PBS, fixed in 4% paraformaldehyde for 30 min, washed again three times with PBS, and stained with 0.1% crystal violet for 30 min. The cells were then observed and quantified under a microscope [29]. Invasion Assay: Transwell chambers pre-coated with Matrigel gel were used for this assay. Subsequent steps were identical to those described for the migration assay. Cell scratch experiment The transfection-treated cells were digested with 0.25% trypsin to prepare a single-cell suspension, counted, and grouped under a microscope. They were then inoculated into six-well plates at a density of 2 × 105/ml, with 1 mL of the suspension added to each well. After incubation in RPMI1640 medium containing 20% fetal bovine serum for 24 h, the medium was replaced with serum-free RPMI1640 medium. Once the cells reached a confluent monolayer under the microscope, a straight line was scratched vertically across the diameter of the six-well plate using a 20 μl yellow pipette tip. The wells were rinsed twice with saline, and 2 mL of RPMI1640 medium was added to each well thereafter. Images were captured under a microscope at 0 h and 24 h. Five distinct migratory points on both sides of the scratch were selected, and the distances were quantified using ImageJ. The average of the three measurements was calculated. Flow cytometry A total of 5 × 10⁵ cells were placed in a 1.5 mL centrifuge tube, washed twice with saline, and the supernatant discarded. The cells were resuspended in 100 μL of PBS. Flow cytometry antibody was added to the experimental tube, and isotype control antibody was added to the control tube. Samples were protected from light and incubated on ice for 20 min. After incubation, the cells were washed once with saline, then resuspended with 500 μL saline, transferred to flow cytometry tubes. Data were acquired on a FACSCanto II flow cytometer and analyzed with Diva software to assess the ratio of induced regulatory T cells (Tregs) in cancerous tissues and paracancerous tissues of patients with esophageal cancer, the proportions of CD4+ and CD8+ T cells, and their functional characteristics. Hematoxylin and eosin staining Hematoxylin and eosin staining was performed to observe structural changes in major organs in mice and to assess the effects of miR-130b and IL-33 downregulation or overexpression on these organs. Tumor model construction A total of 7 × 106 cells/mL in the logarithmic growth phase were subcutaneously injected into the back of BALB/c nude mice. Tumor development was monitored, and the long and short diameters of the tumor were measured every 2 days. Tumor volume was calculated according to the formula: Volume = (length × width²) / 2. Tumor growth curves were generated to assess the in vivo impact of miR-130b and IL-33 down-regulation or overexpression on tumor volume and size. Transfection techniques The constructed plasmids were transfected into packaging cells, and tumor cells were infected with the viral supernatant to knockdown or overexpress IL-33 and miR-130b in esophageal cancer. Small molecule interference techniques These techniques were employed to modulate the expression levels of miR-130b and IL-33, enabling the assessment of their roles in esophageal cancer cell behavior. Bioinformatic prediction miR-130b is predicted to bind to the upstream promoter region of IL-33, while RUNX3 may serve as a transcription factor regulating IL-33 expression. Additionally, computational analysis suggests that miR-130b targets the 3′UTR of RUNX3, indicating a potential regulatory interaction. Dual luciferase reporter experimental assay To investigate the regulatory roles of miR-130b, luciferase reporter vectors containing wild-type and mutant sequences of IL-33 and RUNX3 were constructed. Additionally, constructs harboring wild-type and mutant miR-130b binding sites in the 3′UTR of RUNX3 were generated [30]. Statistical analysis Data were analyzed using IBM SPSS Statistics v21.0 software. For comparisons between the two groups, normality was assessed using the Shapiro–Wilk test, and the chi-square test was used for categorical variables. A t-test was used to compare the means of continuous variables between the experimental and control groups, with the significance level set at p < 0.05. For comparisons involving multiple groups, a one-way analysis of variance (ANOVA) was used, with the F-value calculated to assess the overall effect of the treatment regimen on patient indicators. A repeated-measures ANOVA with Greenhouse-Geisser correction was used to compare differences across time points, followed by Tukey's HSD test for multiple comparisons, with a significance level of p < 0.05. Tumor growth curve data were analyzed using repeated measures ANOVA, considering both time and treatment factors to evaluate their effects, with the corresponding statistics and p-values reported. Survival analysis was performed using the Kaplan–Meier method, with the log-rank test used to compare survival differences between groups, where p<0.05 indicated a significant difference. Additionally, univariate and multivariate analyses, as well as regression methods, were employed to identify the key factors influencing survival. All tests were two-tailed, with a significance level of p < 0.05 [31]. Construction of IL-33 overexpression lentiviral system Full-length primers for IL-33 amplification were designed after checking the human IL-33 sequence in the GenBank database. The pBpLV lentivirus vector was used to identify the multiple cloning site. Restriction enzyme sites SalI and NheI, which are not in the full-length IL-33 gene, were selected for primer design. The IL-33 primers were designed as follows: IL-33PF: GTGACGGTGTTGATGGTAAGAT, IL-33PR: AGCTCCACAGAGTGTTCCTTG. Primers for IL-33 were synthesized by Shanghai Bioengineering and delivered to our laboratory. Full-length IL-33 was amplified by qPCR using a high-fidelity enzyme with cDNA from KYSE-450 cells as a template. The amplified product was cloned into a lentiviral plasmid and used for lentiviral packaging. After viral packaging, the supernatant was collected and used to transduce cells. Stable overexpression of IL-33 in the transduced cell lines was confirmed using flow cytometry. Detection of Transfection Efficiency: Transfected cells were expanded and cultured. Stably transfected cells were collected, and total RNA was extracted. The expression levels of IL-33 were assessed using qPCR. Additionally, protein was extracted from the virus-transduced esophageal squamous carcinoma cells, and the expression level of IL-33 was evaluated using Western blotting. Construction of a lentiviral system with stable knockdown of IL-33 Construction of Lentiviral Plasmid Vector for IL-33: The GenBank ID for IL-33 was NM_001199640. The shRNA sequence targeting IL-33 was synthesized by Shanghai Jimar. The sequence is as follows: (5′ to 3′) GGAGCUCCAUAAGUGUGAATT. Construction and sequencing of the negative control (NC) plasmid and the selected lentiviral plasmid were performed by Shanghai Jikai Genetics Co. Lentiviral Packaging and Transfection: Cells were cultured after resuscitation, and the 293T cell line was inoculated into six-well plates. The Opti-MEM medium was left at room temperature without adding serum or antibiotics. Using a pipette, the 293T cells were aspirated and gently added to Opti-MEM medium at 37 °C along the wall of the well. Two 1.5 mL centrifuge tubes were prepared, each containing Opti-MEM medium. Liposomes and plasmids for transfection were added to each tube, the mixture was vortexed thoroughly and incubated at room temperature for 5 min. Subsequently, the transfection mixture was added to the 293T cells in a six-well plate, and the plate was placed into the incubator for culture. The virus was concentrated and purified by ultrafiltration and ultracentrifugation, and the viral supernatant was collected in centrifuge tubes that can be dispensed and stored in a refrigerator at –80 °C. Results IL-33 is associated with poor prognosis in patients with esophageal cancer The mRNA and protein levels of IL-33 were higher in ESCC tissues than in normal adjacent tissues. Additionally, IL-33 mRNA was highly expressed in ESCC cells, and patients with ESCC in the high IL-33 expression group had a poor prognosis (Fig. 1A) (P < 0.05). Further analysis indicated that the expression level of IL-33 could predict the 3-year prognosis of patients with ESCC (Fig. 1B). The original sequencing data and processed gene expression matrix of the mouse model are stored in the Genome Sequence Archive of the Big Data Center of the Beijing Institute of Genomics, Chinese Academy of Sciences (http://gsa.big.ac.cn). Analysis of single-cell data from mice showed that, compared to the normal esophagus (NOR) stage, cells at the in situ carcinoma (CIS) and invasive carcinoma (ICA) stages of esophageal squamous cell carcinoma demonstrated higher levels of IL-33 and its receptor IL1RL1 (ST2) (Fig. 1C). Our analysis of the prognostic nomogram of patients with ESCC in the TCGA database indicated that IL-33 could predict the prognosis of patients (Fig. 1D). The miRNA and mRNA data were downloaded from UCSC Xena. Correlation analysis was conducted using PD-L1, IL-33, and miRNA data from patients with esophageal cancer. The Spearman correlation test was applied to analyze >300 miRNAs. Blue represents upregulation, red represents downregulation, yellow represents opposite regulatory effects between IL-33 and PD-L1, and purple represents intersecting miRNAs that negatively regulate the two genes. The relationships among IL-33, PD-L1, and miRNAs are presented in a network diagram (Fig. 1E). Seven miRNAs were identified at the intersection of those that negatively regulated both IL-33 and PD-L1 (Fig. 1F). Subsequently, qPCR was used to detect miR-130b mRNA in the tumor tissues of 48 patients with esophageal cancer (Table 1). The expression of miR-130b in tumor tissues was lower than that in normal tissues (P < 0.05) (Fig. 1G), suggesting that it may play a negative regulatory role.Fig. 1IL-33 as a prognostic biomarker and regulatory hub in ESCC(A) In the TCGA database, patients with ESCC in the high IL-33 expression group had a poor prognosis.(B) IL-33 expression level can predict the 3-year prognosis of patients with ESCC.(C) Single-cell sequencing results of mouse ESCC indicated that the expression of IL-33 and its receptor IL1RL1 (ST2) was more prominent in the in-situ carcinoma (CIS) and invasive carcinoma (ICA) stages than in the normal (NOR) stage.(D) The TCGA prognostic nomogram suggested that IL-33 could predict ESCC patient outcomes.(E) Network diagram of the relationship among IL-33, PD-L1, and miRNAs.(F) Seven miRNAs were identified at the negative regulatory intersection.(G) Low expression of miR-130b mRNA in ESCC tissues.ESCC, esophageal squamous cell carcinoma; IL1RL1, interleukin-1 receptor-like 1; ST2, suppression of tumorigenicity 2; CIS, carcinoma in situ; ICA, invasive carcinoma; NOR, normal; PD-L1, programmed death-ligand 1; miRNA, microRNA; TCGA, The Cancer Genome Atlas. *P < 0.05, **P < 0.01, ***P < 0.001.Fig 1 dummy alt textTable 1Clinical and Pathological Parameters of 30 Patients with Esophageal Squamous Cell Carcinoma.Table 1 dummy alt textClinical ParameterNumber of Cases(n)-△△Ct(Target gene)P>1<1Age(years)0.7143≤601082>6020614Gender0.4362Male18810Female1266TNM Stage0.0232Stage Ⅰ16124Stage Ⅱ,Ⅲ,Ⅳ14410 IL-33 as a prognostic biomarker and regulatory hub in ESCC (A) In the TCGA database, patients with ESCC in the high IL-33 expression group had a poor prognosis. (B) IL-33 expression level can predict the 3-year prognosis of patients with ESCC. (C) Single-cell sequencing results of mouse ESCC indicated that the expression of IL-33 and its receptor IL1RL1 (ST2) was more prominent in the in-situ carcinoma (CIS) and invasive carcinoma (ICA) stages than in the normal (NOR) stage. (D) The TCGA prognostic nomogram suggested that IL-33 could predict ESCC patient outcomes. (E) Network diagram of the relationship among IL-33, PD-L1, and miRNAs. (F) Seven miRNAs were identified at the negative regulatory intersection. (G) Low expression of miR-130b mRNA in ESCC tissues. ESCC, esophageal squamous cell carcinoma; IL1RL1, interleukin-1 receptor-like 1; ST2, suppression of tumorigenicity 2; CIS, carcinoma in situ; ICA, invasive carcinoma; NOR, normal; PD-L1, programmed death-ligand 1; miRNA, microRNA; TCGA, The Cancer Genome Atlas. *P < 0.05, **P < 0.01, ***P < 0.001. Table 1Clinical and Pathological Parameters of 30 Patients with Esophageal Squamous Cell Carcinoma.Table 1 dummy alt textClinical ParameterNumber of Cases(n)-△△Ct(Target gene)P>1<1Age(years)0.7143≤601082>6020614Gender0.4362Male18810Female1266TNM Stage0.0232Stage Ⅰ16124Stage Ⅱ,Ⅲ,Ⅳ14410 Clinical and Pathological Parameters of 30 Patients with Esophageal Squamous Cell Carcinoma. Correlation of IL-33 with PD-L1 and miR-130b-mediated regulation of their expression in ESCC The TISIDB database (http://cis.hku.hk/TISIDB/browse.php?gene=IL33) indicated that IL-33 expression level correlated with the expression level of CD274 (PD-L1) in multiple tumors (Fig. 2A). In clinical practice, PD-L1 expression in esophageal squamous cells is a key factor in determining patient eligibility for immune checkpoint inhibitors. Therefore, we hypothesized that IL-33 might affect PD-L1 expression level in ESCC. miR-130b transfection in KYSE-450 and EC-1 cells significantly decreased IL-33 and PD-L1 expression. (Fig. 2C-E).Fig. 2Correlation of IL-33 with PD-L1 and miR-130b-mediated regulation of their expression(A) The TISIDB database suggests that IL-33 expression level correlates with the expression of CD274 (PD-L1) in multiple tumors.(B–E) miR-130b-3p transfection in KYSE-450 and EC-1 cells significantly decreased IL-33 and PD-L1 expression.PD-L1, programmed death-ligand 1; TISIDB, Tumor and Immune System Interaction Database. *P < 0.05, **P < 0.01, ***P < 0.001.Fig 2 dummy alt text Correlation of IL-33 with PD-L1 and miR-130b-mediated regulation of their expression (A) The TISIDB database suggests that IL-33 expression level correlates with the expression of CD274 (PD-L1) in multiple tumors. (B–E) miR-130b-3p transfection in KYSE-450 and EC-1 cells significantly decreased IL-33 and PD-L1 expression. PD-L1, programmed death-ligand 1; TISIDB, Tumor and Immune System Interaction Database. *P < 0.05, **P < 0.01, ***P < 0.001. miR-130b negatively regulates RUNX3, IL-33, and PD-L1 Transfection of EC-1 and KYSE-450 ESCC cells with the miR-130b-3p agomir significantly increased miR-130b expression and decreased IL-33, PD-L1, and RUNX3 levels (P < 0.05; Fig. 3); the antagomir had the opposite effect (P < 0.05).Fig. 3Correlation between IL-33 and PD-L1PCR results indicated that miR-130b negatively regulates RUNX3, IL-33, and PD-L1 expression (in vitro assay).PD-L1, programmed death-ligand 1; PCR, polymerase chain reaction. *P < 0.05, **P < 0.01, ***P < 0.001.Fig 3 dummy alt text Correlation between IL-33 and PD-L1 PCR results indicated that miR-130b negatively regulates RUNX3, IL-33, and PD-L1 expression (in vitro assay). PD-L1, programmed death-ligand 1; PCR, polymerase chain reaction. *P < 0.05, **P < 0.01, ***P < 0.001. MiR-130b regulates IL-33 expression through RUNX3 We analyzed the ENCORI database and found that miR-130b targets RUNX3. The JASPAR database predicted a correlation between miR-130b and RUNX3 (Fig. 4B) and identified their interaction sites (Fig. 4A), which were verified using a dual-luciferase assay. The JASPAR database predicted a binding site for RUNX3 in the IL-33 promoter region, and dual-luciferase experiments further validated that RUNX3 functions as a transcription factor regulating IL-33 expression (Fig. 4C).Fig. 4. MiR-130b regulates IL-33 expression by targeting RUNX3(A) Predicted binding sites between miR-130b and RUNX3.(B) The JASPAR database predicted a correlation between miR-130b and RUNX3 expression.(C) JASPAR, database of transcription factor binding profiles; TCGA, The Cancer Genome Atlas. *P < 0.05, **P < 0.01, ***P < 0.001.Fig 4 dummy alt text . MiR-130b regulates IL-33 expression by targeting RUNX3 (A) Predicted binding sites between miR-130b and RUNX3. (B) The JASPAR database predicted a correlation between miR-130b and RUNX3 expression. (C) JASPAR, database of transcription factor binding profiles; TCGA, The Cancer Genome Atlas. *P < 0.05, **P < 0.01, ***P < 0.001. IL-33 regulates PD-L1 expression and affects the invasion, migration, and progression of esophageal cancer Immunohistochemical and immunofluorescence analysis revealed IL-33 and PD-L1 co-localization in the cytoplasm and cell membrane of esophageal cancer cells. As shown in the merged image, the two proteins exhibit distinct yellow signals in the cytoplasm, suggesting their potential colocalization (Fig. 5A).Flow cytometry analysis further demonstrated that PD-L1 inhibition significantly attenuated the anti-apoptotic effect induced by IL-33 in ESCC cells (Fig. 5B), indicating that PD-L1 functions as a critical downstream mediator of IL-33-driven cell survival. Cell function experiments revealed that IL-33 overexpression promoted the migration, invasion, activity, cloning ability, and proliferation of ESCC cells. When IL-33 overexpression was combined with PD-L1 inhibition, the PD-L1 inhibitor partially reversed IL-33 effects (Fig. 5C,D,E).Fig. 5IL-33 regulates PD-L1 expression and affects the invasion, migration, and progression of esophageal cancer(A) Immunofluorescence staining revealed co-localization of IL-33 and PD-L1.(B) PD-L1 inhibition attenuates the anti apoptotic effect induced by IL 33.(C–E) Administration of miR-130b-3p agomir inhibited IL-33 and PD-L1 expression. IL-33 overexpression promoted the invasion, migration, proliferation, and progression of ESCC cells.IL-33, interleukin-33; PD-L1, programmed death-ligand 1; ESCC, esophageal squamous cell carcinoma. *P < 0.05, **P < 0.01, ***P < 0.001.Fig 5 dummy alt text IL-33 regulates PD-L1 expression and affects the invasion, migration, and progression of esophageal cancer (A) Immunofluorescence staining revealed co-localization of IL-33 and PD-L1. (B) PD-L1 inhibition attenuates the anti apoptotic effect induced by IL 33. (C–E) Administration of miR-130b-3p agomir inhibited IL-33 and PD-L1 expression. IL-33 overexpression promoted the invasion, migration, proliferation, and progression of ESCC cells. IL-33, interleukin-33; PD-L1, programmed death-ligand 1; ESCC, esophageal squamous cell carcinoma. *P < 0.05, **P < 0.01, ***P < 0.001. Verification of miR-130b through animal experiments EC-1 and KYSE-450 cells were transfected with miR-130b agomir, miR-130b antagomir, or control cells. These cells were subcutaneously injected into mice to establish the animal models. After 42 days, tumor growth curves were observed. miR-130b-3p agomir significantly inhibited ESCC growth (Fig. 6A,B). Subcutaneous tumor formation assays showed that injection of the miR-130b agomir significantly reduced tumor volume compared to the control group, with an inhibition rate of 44%. Conversely, after injecting miR-130b-3p antagomir for subcutaneous tumor formation in KYSE-450 cells, the tumor volume was significantly larger than that of the control group, with a promotion rate of 39% (Fig. 6C). Immunohistochemical analysis showed that in a subcutaneous tumor derived from EC-1 cells, miR-130b-3p agomir injection reduced the expression of IL-33, Ki67, and PD-L1. In contrast, in tumors formed from KYSE-450 cells, miR-130b-3p antagomir injection increased the expression of these markers (Fig. 6D,E).Fig. 6In vivo effects of miR-130b-3p on ESCC progression(A) Statistical analysis of tumor growth curves.(B) Comparison diagram of subcutaneous tumor formation.(C) In subcutaneous tumor models, miR-130b-3p agomir injection significantly reduced tumor size in EC-1 cells. Conversely, miR-130b-3p antagomir injection in KYSE-450 cell-derived tumors resulted in increased tumor size.(D.E) HE staining and immunohistochemistry revealed that miR-130b-3p agomir injection in EC-1-derived subcutaneous tumors decreased IL-33, Ki67, and PD-L1 expression. Conversely, miR-130b-3p antagomir injection in KYSE-450-derived tumors increased the expression of these markers.Fig 6 dummy alt text In vivo effects of miR-130b-3p on ESCC progression (A) Statistical analysis of tumor growth curves. (B) Comparison diagram of subcutaneous tumor formation. (C) In subcutaneous tumor models, miR-130b-3p agomir injection significantly reduced tumor size in EC-1 cells. Conversely, miR-130b-3p antagomir injection in KYSE-450 cell-derived tumors resulted in increased tumor size. (D.E) HE staining and immunohistochemistry revealed that miR-130b-3p agomir injection in EC-1-derived subcutaneous tumors decreased IL-33, Ki67, and PD-L1 expression. Conversely, miR-130b-3p antagomir injection in KYSE-450-derived tumors increased the expression of these markers. Supplementary 1 The mTOR signaling pathway not only regulates anti-tumor immunity by enhancing the effector function of immune cells but also directly upregulates PD-L1 expression in cancer cells and synergistically mediates immune escape [32,33]. Aberrant activation of mTOR plays a critical role in malignant transformation and tumor progression, suggesting that targeting the mTOR pathway (e.g., mTORC1-specific inhibition) is a highly promising therapeutic strategy [34]. To clarify the molecular pathways involved, we performed transcriptome sequencing on KYSE450 esophageal cancer cells overexpressing IL-33 and corresponding control cells. A total of 2075 genes showed significant differential expression in KYSE450 cells overexpressing IL-33 compared to the control group, including 1038 upregulated and 1037 downregulated genes (Figure S1A). The upregulated genes in KYSE450 cells overexpressing IL-33 were enriched in the KEGG pathway analysis (Figure S1B). Therefore, we hypothesized that the mTORC1 signaling pathway mediates IL-33–induced PD-L1 expression, thereby contributing to esophageal cancer progression (Figure S1.B,S3A). Supplementary 2 Western blot assay showed that the miR-130b agomir inhibited IL-33 and PD-L1 expression. Transfection of miR-130b agomir into EC-1 and KYSE450 esophageal squamous cell carcinoma cells decreased IL-33 and PD-L1 expression, while transfection with the miR-130b antagomir increased their expression (Figure S2.A,B). Supplementary 3 After treatment with rapamycin, the expression of PD-L1 decreased. Transfection with an IL-33 overexpression plasmid resulted in an increase in PD-L1 expression, and the difference was statistically significant (Figure S3). Supplementary 4 miR-130b directly targets RUNX3, leading to IL-33 downregulation. Secreted IL-33 then binds to its receptor, ST2, thereby activating the mTORC1 pathway. This cascade ultimately induces PD-L1 expression and promotes the progression of esophageal squamous cell carcinoma (Figure S4.). Discussion Previous studies have shown that IL-33/ST2 is affected by the interaction between CAFs and epithelial cells within the tumor microenvironment, and activation of this axis leads to increased expression of inflammatory factors in tumor CAFs and epithelial cells [35,36]. Fibroblast-derived IL-33 promotes tumor cell endocytosis and T-cell-mediated tumor control [37]. Additionally, CAFs express the tumor-supportive properties of IL-33 [38]. Our multi-omics investigation delineates a novel miR-130b-RUNX3-IL33-PD-L1 regulatory axis driving ESCC progression, supported by clinical datasets, in vitro experiments, and in vivo validation. Analysis of TCGA and single-cell sequencing datasets revealed that elevated IL-33 and IL1RL1 expression in tumor tissues correlated with advanced disease stage and poor prognosis in patients with ESCC. This aligns with previous studies implicating IL-33 in fostering pro-tumorigenic microenvironments via immunomodulation and angiogenesis. Notably, our prognostic nomogram identified IL-33 as an independent predictor of ESCC survival, highlighting its clinical relevance. miRNAs can influence PD-L1 expression either by directly targeting PD-L1 mRNA or mediating its post-transcriptional regulation [39]. For example, miR-130b exhibits tumor-type-specific functions: in colorectal cancer, it promotes tumor progression by suppressing CHD9 expression via binding to its 3′UTR [40]; in contrast, in non-small-cell lung cancer, it exerts oncogenic effects through an as-yet-unidentified target, [16] highlighting the pleiotropic roles and molecular heterogeneity of its regulatory network. Notably, we observed a significant co-expression pattern between IL-33 and PD-L1 across multiple cancer types using the TISIDB database, suggesting potential crosstalk between IL-33 signaling and immune checkpoint regulation. Mechanistically, miR-130b has emerged as the central regulator of this axis. qPCR confirmed the downregulation of miR-130b in ESCC tissues compared to the adjacent normal mucosa. Gain- and loss-of-function experiments in KYSE-450 and EC-1 cells further demonstrated that miR-130b inversely modulated RUNX3, IL-33, and PD-L1 expression. ENCORI and JASPAR database analyses coupled with dual-luciferase assays validated miR-130b’s direct targeting of RUNX3 and RUNX3’s transcriptional control of IL-33. These findings elucidated a previously undefined signaling cascade linking epigenetic regulation (miR-130b) to immune checkpoint activation (PD-L1) via IL-33. Several preclinical studies have investigated the correlation between IL-33/ST2 signaling and the antitumor effects of PD-1/PD-L1 ICIs in different tumor models [41,42]. Dual targeting of IL-33 and PD-L1, particularly with the bifunctional fusion protein anti-PD-L1-sST2, induces potent antitumor responses and significantly enhances antitumor activity [43]. Functional studies revealed that IL-33 overexpression enhanced ESCC cell migration, invasion, and proliferation and that these phenotypes were partially reversed by PD-L1 inhibition. Immunohistochemical and co-localization assays further confirmed cytoplasmic/membrane PD-L1 and IL-33 expression in tumor cells, with PD-L1 blockade attenuating IL-33-mediated anti-apoptotic effects. These data, including flow cytometric evidence that PD-L1 blockade reverses IL-33-mediated anti-apoptotic effects, collectively indicate that PD-L1 functions as a critical downstream effector of IL-33′s oncogenic activity, potentially bridging chronic inflammation and immune evasion in ESCC. miR-130b affects colorectal cancer cell proliferation, apoptosis, and tumor growth, suggesting that miR-130b may be a novel oncogene target for the treatment of colorectal cancer [44]. In vivo xenograft models have reinforced the translational implications of this axis. The miR-130b. The function of RUNX3 in gastrointestinal cancers has been predominantly characterized as a tumor suppressor, particularly in gastric cancer. However, the biological activity of transcription factors and cytokines is increasingly recognized as highly context-dependent, varying with tumor type, disease stage, and microenvironmental composition. A paradigmatic example is interleukin-33 (IL-33), which exerts either pro-tumorigenic or anti-tumorigenic effects depending on the specific context [45]. agomir significantly suppressed tumor growth in EC-1- and KYSE-450-derived xenografts, concomitant with reduced IL-33, PD-L1, and Ki67 expression. Conversely, antagomir-mediated miR-130b knockdown accelerated tumor progression, highlighting its tumor-suppressive role. These results mirror the clinical observations and establish miR-130b as a therapeutic candidate for ESCC. In conclusion, our results confirm that IL-33 regulates PD-L1 expression, thereby influencing key oncogenic processes, including invasion, migration, and progression of esophageal cancer. Targeting IL-33 or its downstream signaling could represent a novel therapeutic strategy to modulate PD-L1 expression and enhance the efficacy of immune checkpoint inhibitors in ESCC. Currently, clinical investigations on PD-L1 expression patterns in esophageal squamous carcinoma are limited. Therefore, additional studies are required to establish a comprehensive understanding of IL-33-mediated PD-L1 upregulation in tumor progression and its therapeutic potential as a molecular target. Moreover, the regulatory mechanisms by which PD-L1 modulates the biological behavior of esophageal squamous carcinoma cells require further elucidation. Future studies should explore the downstream mediators of PD-L1 signaling and clarify whether PD-L1 expression directly affects the malignant phenotype of ESCC or modulates anti-tumor immune responses. Funding information Science and Technology Tackling Program of Henan Provincial Science and Technology Department, Project No 232,102,310,120. Competing interests The authors of this article declare that there is no conflict of interest. We have not received any financial support or incentives from any organization or individual that could have influenced the content or outcome of this research. Our work is based solely on scientific inquiry and the pursuit of knowledge to contribute to the field. We are committed to presenting objective and accurate research results and ensuring the integrity and credibility of our work. Any potential conflicts of interest would have been disclosed promptly if they had arisen during the course of our study. We understand the importance of transparency in scientific research and affirm that this declaration reflects the true state of our interests. Ethics statement All animal experiments described in this study were reviewed and approved by the Experimental Animal Welfare Ethics Committee (AEWEC) of Henan Provincial Second People's Hospital. The experimental procedures were designed to minimize animal suffering, including considerations for humane endpoints, anesthesia protocols (or justification for non-anesthesia with mitigating measures), post-experimental handling, and euthanasia. Informed consent N/A Registry and the Registration No of the study/trial N/A. CRediT authorship contribution statement Ying Yue: Writing – original draft. Wei Xian: Supervision, Resources. Yi Yuan: Supervision, Resources. Xinyue Wang: Writing – original draft. Peng Wu: Writing – review & editing. Xiaoyu Sha: Investigation. Xiangyu Yue: Validation. Declaration of competing interest All authors declare that they have no known competing financial interests or personal relationships that could have inappropriately influenced the work reported in this paper. All authors have read and approved the content of this declaration.